Weight loss: Medical guides
Explore the guides, their sources and options for a medical assessment.
Treatments and medicines
Mounjaro before and after: what to expect month by month, according to the trials
Mounjaro can start to show weight loss within the first few weeks, but the first month usually coincides with the 2.5 mg starting dose and is a long way from the final result. Trials and clinical practice point to a gradual trajectory: early changes, further loss at 3 and 6 months and a greater average as you approach the one-year mark, with considerable variation from person to person.
Oct 08, 2026
Mounjaro reviews: what the trials show and what patients report
We separate what the Mounjaro (tirzepatide) trials measured from what patients say: how much weight is lost, digestive side effects, people stopping, cost and what happens when you stop.
Oct 01, 2026
Orforglipron (Foundayo), approved by the FDA: the first GLP-1 pill that can be taken without food or water restrictions
The FDA approved Foundayo (orforglipron) on 1 April 2026 for obesity and overweight with complications. It is a small-molecule oral GLP-1, different from semaglutide, and its phase 3 trial showed an average weight loss of 12.4% at 72 weeks with the 36 mg dose. It is not authorised in Spain: here is what is known, what is not, and why comparisons with Ozempic or Mounjaro do not hold up.
Aug 19, 2026
Survodutide: what it is and where it currently stands
Survodutide is an investigational drug that activates two receptors at once: the GLP-1 receptor and the glucagon receptor. It is in advanced trials for obesity and for liver disease, but it is not yet authorised in Spain. Here is what the data actually show.
Aug 07, 2026
Weight regain after stopping treatment: why it happens and how it is managed
Regaining some weight after stopping a GLP-1 receptor agonist is an expected physiological phenomenon, not a failure of willpower. We explain what the evidence from the semaglutide and tirzepatide trials shows, what comes back and what doesn't, and where things stand in Spain.
Jul 29, 2026
Orforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain
The FDA approved orforglipron in April 2026 under the brand name Foundayo. It is a daily tablet that can be taken at any time of day, with no fasting and no water restriction. It is not authorised in Spain. Here is what its trials actually show.
Jul 17, 2026
Retatrutide: what its phase 3 trial found, and why you can't get hold of it
Lilly announced the TRIUMPH-1 results: −28.3% body weight at 80 weeks. Here's what that figure says, what it doesn't say, and why retatrutide isn't authorised in any country in the world.
Jul 17, 2026
CagriSema: what it is, what the REDEFINE trials found and why it disappointed
Novo Nordisk combined semaglutide with cagrilintide expecting 25% weight loss. It came out at 22.7%, and when it was measured head to head against tirzepatide, it lost. What the data say and where it stands today.
Jul 17, 2026
Ozempic and Mounjaro side effects: what to expect and how to manage them
Ozempic and Mounjaro side effects: what to expect, how they are managed clinically and why proper medical follow-up makes all the difference.
Jun 28, 2026
GLP-1: what it is, how it works and why it is transforming obesity treatment
What the GLP-1 hormone is, how pharmacological GLP-1 agonists work, which medicines are available in Spain (Ozempic, Wegovy, Mounjaro) and what the clinical evidence shows.
Jun 28, 2026
Ozempic in Spain: what it is, how it works and who can take it
What Ozempic is, how it works, who can take it and how to obtain it legally in Spain. An up-to-date medical guide reviewed by a registered endocrinologist.
Jun 28, 2026
Condition and symptoms
Insulin resistance: symptoms, how it is diagnosed and how to reverse it
What insulin resistance is, why it rarely causes symptoms, what a high fasting insulin level means and what has been shown to reverse it: weight, movement, diet, sleep and, where appropriate, medical treatment.
Oct 07, 2026
High triglycerides: why they rise and how to really bring them down
Having high triglycerides does not always mean the same thing. What matters is how raised they are, why they have gone up and whether the main problem is cardiovascular risk or the risk of pancreatitis. This guide explains the most common causes, what is usually checked and what guidelines and studies say about lifestyle and the options available in Spain.
Sep 29, 2026
Polycystic ovary syndrome (PCOS): symptoms, diagnosis and what is known to help
Polycystic ovary syndrome is the most common cause of anovulation worldwide, and up to 70% of women who have it are undiagnosed. We explain what it is, how the diagnosis is reached, what the 2023 international guideline says and where the evidence is still weak.
Sep 08, 2026
Obstructive sleep apnoea: what it is and how it is treated
Obstructive sleep apnoea is a common disorder in which breathing is reduced or stops during the night. Here is what causes it, how it is diagnosed and which treatment options the evidence supports today.
Aug 17, 2026
Metabolic syndrome: what it is, why it happens and how it is managed
Metabolic syndrome is not a single disease but a cluster of risk factors that tend to travel together: waist, blood sugar, blood pressure and blood fats. Here is what the evidence says, how common it is in Spain and what genuinely works to lower the risk.
Aug 11, 2026
Prediabetes: what it is and how it is managed
Prediabetes is not an established disease, but a state of risk. We explain what the numbers mean, why it matters beyond blood sugar and what the evidence says about how to manage it.
Aug 03, 2026
Metabolic fatty liver disease: what it is, why it happens and what can be done
Metabolic fatty liver disease (MASLD) affects more than 30% of adults and is closely tied to weight, insulin resistance and diabetes. Here we explain what it is, why it happens, what the evidence says about losing weight and the new medicines, and which myths are worth dismantling.
Jul 20, 2026
Guides, prices and comparisons
How much does Mounjaro cost per month in Spain: the real price per dose in 2026
Mounjaro is not funded by the public health system, so the price of the box is what you pay. We go through the indicative retail prices by dose, the detail almost nobody mentions (a year means 13 boxes, not 12) and what the first year really costs once dose escalation is factored in.
Aug 24, 2026
Rybelsus price in Spain: cost per dose (3, 7 and 14 mg) and per month
In Spain, Rybelsus requires a medical prescription. We go through what the classic 3, 7 and 14 mg presentations cost per dose and per month, what changed in 2026 with the new formulation and what that means when you look up prices today.
Sep 23, 2026
Ozempic price in Spain: how much it costs per pen and per month in 2026
There is no single price for Ozempic in Spain in 2026: it depends on the presentation and the number of doses in the pen. This is what is known about the cost per pen, the approximate cost per 4 weeks and how public funding works.
Sep 21, 2026
Buying Ozempic and Mounjaro in Spain: how to get them legally and safely
How to obtain Ozempic and Mounjaro legally in Spain. The legitimate routes, the risks of buying without a prescription, real prices and what to look for in a serious medical service.
Jun 28, 2026
Mounjaro vs Ozempic: clinical differences, effectiveness and which one suits you
A clinical comparison of Mounjaro (tirzepatide) and Ozempic (semaglutide): mechanisms of action, effectiveness in the SURMOUNT and STEP trials, and how the right choice depends on your profile.
Jun 28, 2026
How much does a medical weight loss treatment cost in Spain: complete 2026 guide
How much it costs to lose weight with medical treatment in Spain: a breakdown of consultations, medication, follow-up and supplementation. Comparison and prices.
Jun 28, 2026
Nutraceuticals and supplements
Vitamin D: what the evidence does (and doesn't) say about supplementing
Vitamin D is probably the most widely taken and least well understood supplement of all. We look at what the large randomised trials show on cancer, heart disease, fractures and respiratory infections, what levels are actually measured in Spain, and why the AEMPS has had to warn about poisoning from overdosing.
Aug 28, 2026
Ashwagandha: what it is, what the evidence says and why several European countries have restricted it
Ashwagandha is the star plant on the supplement shelves: it promises calm, less stress and better sleep. The evidence shows a small effect on anxiety and cortisol, while several European agencies have raised red flags over the liver and the thyroid. Here is what is known, what is not, and where it stands from a regulatory point of view in Spain.
Aug 17, 2026
Assessment and follow-up
Learn about the medical assessment and follow-up process.
View the assessment